CATALYSTBenzinga • 1d ago
Morgan Stanley Maintains Overweight on Cardinal Health, Raises Price Target to $286Morgan Stanley analyst Erin Wright maintains Cardinal Health (NYSE:CAH) with a Overweight and raises the price target from $265 to $286.
Why CAH Stock surged +2.59% Today — RQD Quant Desk Flash
$251.09 +2.59% NYSE • Public Delayed / 60s Snapshot
Cardinal Health Inc. (CAH) receives a Roarable Rating of D+ (Sell) and flashes a Red SELL / AVOID warning (66/100 RQD Confidence). Our SEC filing scanner spotted paper earnings outpacing real operating cash flow (+119.5% (NI vs OCF)) while unpaid customer invoices grew—a classic sign to step aside until cash flow catches up.
ROARABLE D+ • SELL / AVOID
Cap $58.14B
INTERACTIVE SCENARIO DECK:
RQD QUANT TACHOMETERSELL / AVOID • D+
JEV AI Jury Split (Battleground)
Cash
SEC
Whale
5-PILLAR SNOWFLAKE RADARRw C · Rk D
Each axis scored 0–20
12M PRICE TARGET CONE+3.6% Base Target
WHALE OPTIONS TUG-OF-WAR:61% Call Buyers ($6.4M)
39% PutsMax Pain: $246.00
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why CAH Stock surged +2.59% Today — RQD Quant Desk Flash
Cardinal Health Inc. (CAH) surged +2.59% to $251.09 as options desks priced 61% call premium vs. 39% put protection around the $246 max-pain magnet. Accounting Warning: Paper earnings outpaced operating cash flow (+119.5% (NI vs OCF)) as receivables rose.
- ▸Technical Tape: Trading at 89% of its 52-week range ($180.45 – $259.84) with RSI-14 at 58.5 (BULLISH MOMENTUM).
- ▸Whale Options Positioning: $6.4M in bullish call flow vs. $4.0M in put flow (Put/Call 0.63x, implied earnings swing ±6.6%).
- ▸Primary SEC / Cross-Feed Trigger: CAH Accounting Gap: Net Income (+83.2%) Outpaced OCF (-36.3%) With +16% Working-Capital Build
Live CAH Headlines & Catalysts
MARKET WIREYahoo • 1d ago
Is Buying McKesson Stock Near Its High A Bad Idea?For questions about this article or underlying research, email help@trefis.com.
MARKET WIREYahoo • 2d ago
Is It A Mistake To Buy Cardinal Health Stock At A High?For questions about this article or underlying research, email help@trefis.com.
MARKET WIREYahoo • 2d ago
West Pharmaceutical Services (WST) Q3 Earnings and Revenues Top EstimatesWest Pharmaceutical (WST) delivered earnings and revenue surprises of +22.02% and +5.88%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
MARKET WIREYahoo • 4d ago
Cardinal Health (CAH) Stock Slides as Market Rises: Facts to Know Before You TradeCardinal Health (CAH) reached $246.45 at the closing of the latest trading day, reflecting a -2.02% change compared to its last close.
MARKET WIREYahoo • 4d ago
Dow Jones Biotech Giant Amgen Breaks Out Ahead Of Q3 Earnings ResultsDow Jones biotech giant Amgen stock is trying to break out past a new buy point ahead of the firm's Q3 earnings report.
CATALYSTYahoo • 4d ago
Amgen vs. Novo Nordisk: Which Healthcare Giant's Stock Is a Better Buy in 2026?Amgen's 9.9% revenue growth outpaces Novo Nordisk, but a 33.1% net margin and lower valuation multiples tell a different profitability story.
CATALYSTYahoo • 7d ago
Amgen vs. Johnson & Johnson: Which Healthcare Giant Has the Better Stock to Buy?Amgen trades at a lower valuation multiple, but Johnson & Johnson's fortress balance sheet and stronger free cash flow tell a different story about financial resilience.
CATALYSTYahoo • 9d ago
Amgen vs. Eli Lilly: Does the GLP-1 Mania Make LLY Stock a Better Buy in 2026?Amgen trades at half the valuation multiple of Eli Lilly while generating stronger free cash flow, but explosive growth in obesity drugs tells a different story.
MARKET WIREYahoo • 9d ago
Should Upcoming Earnings Expectations Require Action From Cardinal Health Stock Investors?Cardinal Health is preparing to report earnings in early November 2026, with forecasts pointing to higher earnings per share and revenue compared with the prior year. The upcoming results are expected to highlight how th
🔴 SUNDAY NIGHT PREP • 7:00 PM ETHosted Live by Perry Belcher & Guest Forensic Quant Desk
Red-Light Warning Desk: How Pros Profit When Overhyped Stocks Crack (Featuring CAH)
- ✓Live walkthrough of CAH's RQD Radar, SEC cash-conversion gap & downside levels
- ✓3 asymmetric Bear/Hedge setups institutions use when 10-year yields stay elevated
- ✓Includes instant 24/7 email alert whenever any of your stocks flip to Red
RQD INSIDER CLUB UPGRADE$49/YEAR
Want Plain-English AI Custom Indicators, Daily Pro Trader Video Clips & SMS Crash Alerts?
CAH // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +29.86%📐 HORIZONTAL RANGE
2026-10-30O $255.0H $259.8L $250.1C $250.5VOL 1.95M
RES: $292.7SUP: $214.9SMA50: $237.8SMA200: $222.2
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
CAH Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
28.5%/yr Implied 5Y Growth
vs. -1.9% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on CAH today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for CAH. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for CAH today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
CAH Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is CAH stock moving today?
Why CAH Stock surged +2.59% Today — RQD Quant Desk Flash. Accounting Warning: Paper earnings outpaced operating cash flow (+119.5% (NI vs OCF)) as receivables rose.